– USA, MA – Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company, announced the appointment of the current Lead Independent Director, Gino Santini, as the next Chairman of its Board of Directors at the AGM on May 15, 2025, to succeed founder Mike Heffernan who will retire from the Board.
Additionally, the company nominated Dr. Carlos Paya (MD, Ph.D.) for his election to its Board of Directors at the AGM.
The company also announced the retirement of Gwen Melincoff from the Board at the AGM.
About Dr. Carlos Paya
Dr. Carlos Paya is a Venture Partner at Abingworth LLP. His career spans over 30 years as a leading physician-scientist in immunology and a senior executive in the biopharmaceutical industry. He serves as the Board Chairman for Vaxcyte, Inc. and Highlight Therapeutics S.L. He serves as a Senior Advisor to Ysios Capital and Launch Therapeutics.
Dr. Carlos Paya served as a member of the board of directors and Chairman of Standard BioTools, Inc. and Mallinckrodt Pharmaceuticals. Most recently, he was the CEO and President of Immune Design Corp. until Merck’s 2019 acquisition. Previously, he was the President of Elan Pharmaceuticals. Dr. Paya also spent several years at Eli Lilly in roles of increasing responsibility, including Global Head for the Diabetes and Endocrine Franchise. He started his career in academics as a Professor of Medicine, Immunology and Pathology at the Mayo Medical School. During his tenure at the Mayo Clinic, Dr. Carlos Paya served as the Vice-Dean for the Clinical Investigation Program.
Dr. Carlos Paya has an M.D. and Ph.D. from the Complutense University of Madrid and underwent postdoctoral training at the Institute Pasteur, Paris, France.
About Collegium Pharmaceutical, Inc.
Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and recently acquired Jornay PM, a treatment for ADHD, establishing a presence in neuropsychiatry. Collegium’s strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts.
For more: https://www.collegiumpharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.